ABBV Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 22:02):
Our systems believe the stock currently is undervalued by 0.04% compare to its pairs and should correct upwards.

Stats
Tagesvolumen	20.84M
Durchschnittsvolumen	5.35M
Marktkapitalisierung	302.88B
EPS	$0.770 ( Q1 \| 2024-05-03 )
Nächstes Ertragsdatum	( $3.06 ) 2024-07-25
Last Dividend	$1.550 ( 2024-04-12 )
Next Dividend	$0 ( N/A )
P/E	51.05 (Sector) 49.64 (Industry) 72.79
ATR14	$0.115 (0.07%)

ABBV 1.50%

AZN -0.24%

BMY 0.05%

CELG-RI -8.89%

GSK -0.36%

JNJ 0.25%

LLY -0.40%

MRK -4.64%

NVS -0.08%

OGN 0.53%

PFE 0.65%

Insider Trading

Date	Person	Action	Amount	type
2024-05-03	Davis Jennifer L.	Buy	1 322	Common Stock, $0.01 par value
2024-05-03	Quaggin Susan E	Buy	1 322	Common Stock, $0.01 par value
2024-05-03	Rapp Edward J	Buy	1 322	Common Stock, $0.01 par value
2024-05-03	Alpern Robert J	Buy	1 322	Common Stock, $0.01 par value
2024-05-03	Freyman Thomas C	Buy	1 322	Common Stock, $0.01 par value

INSIDER POWER
-22.11
Last 100 transactions
Buy: 589 844 \| Sell: 912 577

Korrelation (AI algo v.1.1b): Undervalued: 0.04% $171.42 paired level. (Der Algorithmus verfolgt in Echtzeit die Änderungen der am stärksten korrelierten Aktien und gibt eine sofortige Aktualisierung)

Volumen Korrelation

Lang: 0.62 (weak)

Kurz: 0.82 (strong)

Signal:(69.801) Same movement expected

Abbvie Inc Korrelation

10 Am meisten positiv korreliert
CNDA-UN	0.939
SBXC	0.933
BWLP	0.918
HAFN	0.898
VLTO	0.89
PACS	0.885
GIB	0.883
AMBP	0.881
GEV	0.881
OBDC	0.88

10 Am meisten negativ korreliert
BYON	-0.947
QBTS	-0.946
PSQH	-0.938
AMBI	-0.932
SRFM	-0.931
CCG	-0.928
MPU	-0.91
GETR	-0.908
EP-PC	-0.906
RIV-PA	-0.901

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Abbvie Inc Korrelation - Währung/Rohstoff

0.29
( neutral )

-0.02
( neutral )

0.00
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.04
( neutral )

Abbvie Inc Finanzdaten

Annual	2023
Umsatz:	$54.32B
Bruttogewinn:	$45.54B (83.84 %)
EPS:	$2.73

FY	2023
Umsatz:	$54.32B
Bruttogewinn:	$45.54B (83.84 %)
EPS:	$2.73

FY	2022
Umsatz:	$58.05B
Bruttogewinn:	$40.64B (70.00 %)
EPS:	$6.65

FY	2021
Umsatz:	$56.20B
Bruttogewinn:	$38.75B (68.96 %)
EPS:	$6.53

Financial Reports:

No articles found.

Abbvie Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.410 (N/A)	$1.410 (N/A)	$1.480 (N/A)	$1.480 (N/A)	$2.96 (N/A)	$1.480 (N/A)	$1.550 (N/A)	$1.550 (N/A)	$0 (N/A)	$0 (N/A)

Abbvie Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.71 - Stable (34.12%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.400	2013-01-11
Last Dividend	$1.550	2024-04-12
Next Dividend	$0	N/A
Payout Date	2024-05-15
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	$44.05	--
Avg. Dividend % Per Year	3.70%	--
Score	5.96	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.71
Div. Directional Score	8.37	--

Next Divdend (Est)
(2024-09-30)

$1.580 Estimate 75.00 %

Dividend Stability

1.00 Excellent

Dividend Score

5.96

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2013	$1.600	4.56%
2014	$1.660	3.19%
2015	$2.02	3.07%
2016	$2.28	3.96%
2017	$2.56	4.10%
2018	$3.59	3.65%
2019	$4.28	4.80%
2020	$4.72	5.27%
2021	$5.20	4.93%
2022	$5.64	4.16%
2023	$7.40	4.56%
2024	$3.10	1.94%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
12 Apr 2024	$1.550	15 Feb 2024	15 Apr 2024	15 May 2024
12 Jan 2024	$1.550	27 Oct 2023	16 Jan 2024	15 Feb 2024
12 Oct 2023	$1.480	08 Sep 2023	13 Oct 2023	15 Nov 2023
14 Jul 2023	$1.480	22 Jun 2023	14 Jul 2023	15 Aug 2023
13 Jul 2023	$1.480	22 Jun 2023	14 Jul 2023	15 Aug 2023
13 Apr 2023	$1.480	16 Feb 2023	14 Apr 2023	15 May 2023
12 Jan 2023	$1.480	28 Oct 2022	13 Jan 2023	15 Feb 2023
13 Oct 2022	$1.410	09 Sep 2022	14 Oct 2022	15 Nov 2022
14 Jul 2022	$1.410	23 Jun 2022	15 Jul 2022	15 Aug 2022
13 Apr 2022	$1.410	17 Feb 2022	15 Apr 2022	16 May 2022
13 Jan 2022	$1.410	29 Oct 2021	14 Jan 2022	15 Feb 2022
14 Oct 2021	$1.300	10 Sep 2021	15 Oct 2021	15 Nov 2021
14 Jul 2021	$1.300	17 Jun 2021	15 Jul 2021	16 Aug 2021
14 Apr 2021	$1.300	18 Feb 2021	15 Apr 2021	14 May 2021
14 Jan 2021	$1.300	30 Oct 2020	15 Jan 2021	16 Feb 2021
14 Oct 2020	$1.180	11 Sep 2020	15 Oct 2020	16 Nov 2020
14 Jul 2020	$1.180	17 Jun 2020	15 Jul 2020	14 Aug 2020
14 Apr 2020	$1.180	20 Feb 2020	15 Apr 2020	15 May 2020
14 Jan 2020	$1.180	01 Nov 2019	15 Jan 2020	14 Feb 2020
11 Oct 2019	$1.070	06 Sep 2019	15 Oct 2019	15 Nov 2019

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
ECC	Dividend Diamond	2024-07-11	Monthly	11	14.91%	9.72
BRW	Dividend Diamond	2024-06-11	Monthly	33	9.41%	9.26
VVR	Dividend Diamond	2024-06-18	Monthly	27	8.85%	9.19
FCT	Dividend Diamond	2024-06-03	Monthly	21	8.33%	9.14
PHK	Dividend Diamond	2024-06-13	Monthly	22	9.07%	9.13
SBR	Dividend Diamond	2024-06-17	Monthly	38	9.57%	9.10
XFLT	Dividend Diamond	2024-06-17	Monthly	8	10.49%	9.09
SRV	Dividend Royal	2024-07-16	Monthly	18	10.61%	9.04
FAM	Dividend Royal	2024-06-03	Monthly	20	8.07%	8.98
RA	Dividend Diamond	2024-06-11	Monthly	9	10.10%	8.93

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.110	1.500	7.80	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0403	1.200	8.66	10.00	[0 - 0.3]
returnOnEquityTTM	0.553	1.500	4.96	7.45	[0.1 - 1]
payoutRatioTTM	1.777	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.936	0.800	-0.319	-0.255	[1 - 3]
quickRatioTTM	0.723	0.800	-0.453	-0.363	[0.8 - 2.5]
cashRatioTTM	0.435	1.500	8.69	10.00	[0.2 - 2]
debtRatioTTM	0.497	-1.500	1.715	-2.57	[0 - 0.6]
interestCoverageTTM	7.24	1.000	8.43	8.43	[3 - 30]
operatingCashFlowPerShareTTM	12.82	2.00	5.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	12.37	2.00	3.81	7.63	[0 - 20]
debtEquityRatioTTM	9.24	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.684	1.000	1.934	1.934	[0.2 - 0.8]
operatingProfitMarginTTM	0.263	1.000	6.75	6.75	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.307	1.000	9.41	9.41	[0.2 - 2]
assetTurnoverTTM	0.365	0.800	-0.897	-0.718	[0.5 - 2]
Total Score				10.03

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	50.63	1.000	4.99	0	[1 - 100]
returnOnEquityTTM	0.553	2.50	6.76	7.45	[0.1 - 1.5]
freeCashFlowPerShareTTM	12.37	2.00	5.88	7.63	[0 - 30]
dividendYielPercentageTTM	3.53	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	12.82	2.00	5.73	10.00	[0 - 30]
payoutRatioTTM	1.777	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	3.54	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.417	1.000	2.08	0	[0.1 - 0.5]
Total Score				6.71

Abbvie Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Abbvie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.